Journal publications

Export 68 results:
[ Author(Desc)] Title Type Year
Filters: Type is Journal Article  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Antiretroviral Therapy Cohort Collaboration(ART-CC), Canadian Observational Cohort Collaboration(CANOC), UK Collaborative HIV Cohort Study(UK CHIC), Collaboration of Observational HIV Epidemiological Research in Europe(COHERE).  2016.  Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. AIDS. 30(3)
Assoumou L., Brun-Vezinet F., Cozzi-Lepri A, Kuritzkes D., Phillips A, Zolopa A., Degruttola V., Miller V., Costagliola D..  2008.  Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis. 198:470-80.
B
Bansi L, Geretti A M, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A et al..  2010.  Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr. 53:633-9.
Bansi L, Smith C, Phillips A, Kirk S., Geretti A M, Johnson M, Mackie NE, Post FA, Gazzard B, Dunn D et al..  2011.  The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.
Barber TJ, Harrison LJ, Asboe D, Williams I, Kirk S., Gilson R, Bansi L, Pillay D, Dunn D.  2012.  Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 67:995-1000.
Bulteel N, Bansi-Matharu L., Churchill D, Dunn D, Bibby D., Hill T, Sabin C, Nelson M.  2014.  The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect. 68:77-84.
C
Cane P A, Chrystie I, Dunn D, Evans B., Geretti A M, Green H, Phillips A, Pillay D, Porter K, Pozniak A et al..  2005.  Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 331:1368.
Cane P A, Green H, Fearnhill E, Dunn D.  2007.  Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS. 21:447-55.
Castro H, Pillay D, Cane P A, Asboe D, Cambiano V, Phillips A, Dunn D.  2013.  Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 208:1459-63.
Castro H, Pillay D, Sabin C, Dunn D.  2012.  Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. BMC Med Res Methodol. 12:30.
Chakraborty R., Smith CJ, Dunn D, Green H, Duong T., Doerholt K., Riordon A., Lyall H., Tookey P, Butler K. et al..  2008.  HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J. 27:457-9.
Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B., Pillay D, Dunn D.  2010.  HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther. 15:985-91.
Collins IJ, Foster C, Tostevin A, Tookey P, Riordan A, Dunn D, Gibb DM, Judd A.  2017.  Clinical Status of Adolescents with Perinatal HIV at Transfer to Adult Care in the UK/Ireland. Clin Infect Dis. Epub ahead of print
Cozzi-Lepri A, Prosperi M.C, Kjaer J., Dunn D, Paredes R., Sabin C, Lundgren J.D, Phillips A, Pillay D.  2011.  Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score PLoS One. 6:e25665.
Cozzi-Lepri A.  2008.  Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. HIV Med. 9:27-40.
D
De Luca A., Dunn D, Zazzi M, Camacho R., Torti C., Fanti I., Kaiser R., Sonnerborg A., Codoner F.M, Van Laethem K. et al..  2013.  Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207:1216-20.
De Luca A., Flandre P., Dunn D, Zazzi M, Wensing A., Santoro MM, Gunthard H.F, Wittkop L., Kordossis T., Garcia F. et al..  2016.  Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. J Antimicrob Chemother. 71:1352-60.
de Oliveira T, Pillay D, Gifford RJM.  2010.  The HIV-1 subtype C epidemic in South America is linked to the United Kingdom. PLoS One. 5:e9311.
Dolling D, Phillips A, Delpech V, Pillay D, Cane P A, Crook A.M, Shepherd J., Fearnhill E, Hill T, Dunn D.  2012.  Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med. 13:309-14.
Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Leigh Brown A.J, Churchill D, Williams I, Geretti A M et al..  2012.  Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ. 345:e5253.